Lisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Promising preliminary Phase 2b (ASCEND) pancreatic cancer data (Cohort A) reported with Cohort B data anticipated in the coming months

Enrollment completed in Qilu’s Phase 2 trial evaluating certepetide for the treatment of first-line mPDAC

Read more at globenewswire.com